利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

60 条记录 (耗时 0.026 秒)

    Drug carrier and drug carrier kit for inhibiting fibrosis
    2.
    发明授权
    Drug carrier and drug carrier kit for inhibiting fibrosis 有权
    用于抑制纤维化的药物载体和药物载体试剂盒

    公开(公告)号：US08652526B2

    公开(公告)日：2014-02-18

    申请号：US13439330

    申请日：2012-04-04

    申请人： Yoshiro Niitsu ,  Junji Kato ,  Yasushi Sato

    发明人： Yoshiro Niitsu ,  Junji Kato ,  Yasushi Sato

    IPC分类号： A61K9/127 ,  A61K9/14 ,  A61K31/07 ,  C12N15/11 ,  A61K38/18

    CPC分类号： A61K31/07 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/14 ,  A61K31/7088 ,  A61K38/1833 ,  A61K38/1841 ,  A61K38/1858 ,  A61K45/06 ,  A61K47/6911 ,  Y10S514/893 ,  Y10T428/2982 ,  A61K2300/00

    摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

    摘要翻译： 含有类视黄醇衍生物和/或维生素A类似物作为成分的星形胶质细胞特异性药物载体; 一种使用该药物的药物递送方法; 含有该药物的药物; 以及使用该药物的治疗方法。 通过将药物载体与维生素A或维生素A类似物的类视黄醇衍生物结合或将其包封在药物载体中，用于治疗用途的药物可以特异性递送至星形胶质细胞。 结果，可以有效地有效地抑制或预防星形胶质细胞相关疾病，同时尽量减少副作用。 作为抑制星形胶质细胞活性或生长的药物，例如可以将作为胶原特异性分子伴侣的HSP47的siRNA包封在药物载体中。 因此，可以同时抑制I型至IV型胶原的分泌，从而可以有效地抑制纤维化。

    Drug Carrier and Drug Carrier Kit for Inhibiting Fibrosis
    3.
    发明申请
    Drug Carrier and Drug Carrier Kit for Inhibiting Fibrosis 有权
    用于抑制纤维化的药物载体和药物载体试剂盒

    公开(公告)号：US20080193512A1

    公开(公告)日：2008-08-14

    申请号：US11793736

    申请日：2005-12-22

    申请人： Yoshiro Niitsu ,  Junji Kato ,  Yasushi Sato

    发明人： Yoshiro Niitsu ,  Junji Kato ,  Yasushi Sato

    IPC分类号： A61K9/127 ,  A61K31/07 ,  A61P35/00

    CPC分类号： A61K31/07 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/14 ,  A61K31/7088 ,  A61K38/1833 ,  A61K38/1841 ,  A61K38/1858 ,  A61K45/06 ,  A61K47/6911 ,  Y10S514/893 ,  Y10T428/2982 ,  A61K2300/00

    摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

    摘要翻译： 含有类视黄醇衍生物和/或维生素A类似物作为成分的星形胶质细胞特异性药物载体; 一种使用该药物的药物递送方法; 含有该药物的药物; 以及使用该药物的治疗方法。 通过将药物载体与维生素A或维生素A类似物的类视黄醇衍生物结合或将其包封在药物载体中，用于治疗用途的药物可以特异性递送至星形胶质细胞。 结果，可以有效地有效地抑制或预防星形胶质细胞相关疾病，同时尽量减少副作用。 作为抑制星形胶质细胞活性或生长的药物，例如可以将作为胶原特异性分子伴侣的HSP47的siRNA包封在药物载体中。 因此，可以同时抑制I型至IV型胶原的分泌，从而可以有效地抑制纤维化。

    Drug carrier and drug carrier kit for inhibiting fibrosis
    4.
    发明授权
    Drug carrier and drug carrier kit for inhibiting fibrosis 有权

    公开(公告)号：US08591953B2

    公开(公告)日：2013-11-26

    申请号：US13439330

    申请日：2012-04-04

    申请人： Yoshiro Niitsu ,  Junji Kato ,  Yasushi Sato

    发明人： Yoshiro Niitsu ,  Junji Kato ,  Yasushi Sato

    IPC分类号： A61K9/127 ,  A61K9/14 ,  A61K31/07 ,  C12N15/11 ,  A61K38/18

    摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

    DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS
    6.
    发明申请
    DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS 有权
    用于抑制纤维化的药物载体和药物载体工具包

    公开(公告)号：US20120076852A1

    公开(公告)日：2012-03-29

    申请号：US13249072

    申请日：2011-09-29

    申请人： Yoshiro Niitsu ,  Junji Kato ,  Yasushi Sato

    发明人： Yoshiro Niitsu ,  Junji Kato ,  Yasushi Sato

    IPC分类号： A61K47/10 ,  A61P1/16 ,  A61P1/18 ,  C07C35/18 ,  A61P11/04 ,  A61K31/7088 ,  A61K48/00 ,  A61K9/127 ,  A61P35/00

    CPC分类号： A61K31/07 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/14 ,  A61K31/7088 ,  A61K38/1833 ,  A61K38/1841 ,  A61K38/1858 ,  A61K45/06 ,  A61K47/6911 ,  Y10S514/893 ,  Y10T428/2982 ,  A61K2300/00

    摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

    摘要翻译： 含有类视黄醇衍生物和/或维生素A类似物作为成分的星形胶质细胞特异性药物载体; 一种使用该药物的药物递送方法; 含有该药物的药物; 以及使用该药物的治疗方法。 通过将药物载体与维生素A或维生素A类似物的类视黄醇衍生物结合或将其包封在药物载体中，用于治疗用途的药物可以特异性递送至星形胶质细胞。 结果，可以有效地有效地抑制或预防星形胶质细胞相关疾病，同时尽量减少副作用。 作为抑制星形胶质细胞活性或生长的药物，例如可以将作为胶原特异性分子伴侣的HSP47的siRNA包封在药物载体中。 因此，可以同时抑制I型至IV型胶原的分泌，从而可以有效地抑制纤维化。

    Pharmaceutical composition for treatment of hepatic diseases
    7.
    发明授权
    Pharmaceutical composition for treatment of hepatic diseases 失效
    用于治疗肝病的药物组合物

    公开(公告)号：US06268336B1

    公开(公告)日：2001-07-31

    申请号：US09202614

    申请日：1998-12-18

    申请人： Yoshiro Niitsu ,  Junji Kato ,  Masato Higuchi

    发明人： Yoshiro Niitsu ,  Junji Kato ,  Masato Higuchi

    IPC分类号： A61K3816

    CPC分类号： A61K38/1816

    摘要： The present invention relates to a pharmaceutical composition for treatment of hepatic diseases which comprises erythropoietin as an active ingredient to reduce excess iron ions in the liver of a mammal with hepatic diseases, thus improving hepatic functions of said mammal. According to the present pharmaceutical composition with erythropoietin as an active ingredient, excess iron ions in the liver of a mammal with hepatic diseases can be decreased, so it is effective for treatment of chronic hepatitis, hepatic carcinoma, hepatocirrhosis etc. due to excess iron ions. Further, patient's anemia accompanying venesection can be prevented while excretion of excess iron ions can be promoted by using the venesection therapy in combination with the administration of said pharmaceutical composition. Furthermore, the pharmaceutical composition of the present invention is administered into a patient with chronic hepatitis C for whom IFN therapy is not effective to improve hepatic functions after which conventional IFN therapy is conducted whereby its therapeutic effect on said hepatitis can be expected.

    摘要翻译： 本发明涉及一种用于治疗肝病的药物组合物，其包含红细胞生成素作为活性成分，以减少具有肝脏疾病的哺乳动物肝脏中过量的铁离子，从而改善所述哺乳动物的肝功能。 根据本发明的具有红细胞生成素作为活性成分的药物组合物，可以减少具有肝脏疾病的哺乳动物肝脏中的过量铁离子，因此由于过量的铁离子对治疗慢性肝炎，肝癌，肝硬化等有效 。 此外，通过与所述药物组合物的给药相结合，可以通过使用Venesection治疗来促进排泄过量铁离子，同时可以预防患有血液循环的贫血。 此外，将本发明的药物组合物施用于慢性丙型肝炎患者，其中IFN治疗对于改善肝功能无效，之后进行常规IFN治疗，从而可以预期其对所述肝炎的治疗效果。

    DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS
    8.
    发明申请
    DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS 有权
    用于抑制纤维化的药物载体和药物载体工具包

    公开(公告)号：US20130011464A2

    公开(公告)日：2013-01-10

    申请号：US13439330

    申请日：2012-04-04

    申请人： Yoshiro Niitsu ,  Junji Kato ,  Yasushi Sato

    发明人： Yoshiro Niitsu ,  Junji Kato ,  Yasushi Sato

    IPC分类号： A61K47/10 ,  A61K9/14 ,  A61K38/18 ,  A61K31/713 ,  A61P1/16 ,  A61K38/17 ,  A61P31/14 ,  A61P35/00 ,  A61P1/18 ,  A61K9/127 ,  A61K31/7088

    CPC分类号： A61K31/07 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/14 ,  A61K31/7088 ,  A61K38/1833 ,  A61K38/1841 ,  A61K38/1858 ,  A61K45/06 ,  A61K47/6911 ,  Y10S514/893 ,  Y10T428/2982 ,  A61K2300/00

    摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

    摘要翻译： 含有类视黄醇衍生物和/或维生素A类似物作为成分的星形胶质细胞特异性药物载体; 一种使用该药物的药物递送方法; 含有该药物的药物; 以及使用该药物的治疗方法。 通过将药物载体与维生素A或维生素A类似物的类视黄醇衍生物结合或将其包封在药物载体中，用于治疗用途的药物可以特异性递送至星形胶质细胞。 结果，可以有效地有效地抑制或预防星形胶质细胞相关疾病，同时尽量减少副作用。 作为抑制星形胶质细胞活性或生长的药物，例如可以将作为胶原特异性分子伴侣的HSP47的siRNA包封在药物载体中。 因此，可以同时抑制I型至IV型胶原的分泌，从而可以有效地抑制纤维化。

    Drug carrier and drug carrier kit for inhibiting fibrosis
    9.
    发明授权
    Drug carrier and drug carrier kit for inhibiting fibrosis 有权
    用于抑制纤维化的药物载体和药物载体试剂盒

    公开(公告)号：US08173170B2

    公开(公告)日：2012-05-08

    申请号：US11793736

    申请日：2005-12-22

    申请人： Yoshiro Niitsu ,  Junji Kato ,  Yasushi Sato

    发明人： Yoshiro Niitsu ,  Junji Kato ,  Yasushi Sato

    IPC分类号： A61K9/127 ,  A61K9/14 ,  A61K31/07 ,  C12N15/11

    CPC分类号： A61K31/07 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/14 ,  A61K31/7088 ,  A61K38/1833 ,  A61K38/1841 ,  A61K38/1858 ,  A61K45/06 ,  A61K47/6911 ,  Y10S514/893 ,  Y10T428/2982 ,  A61K2300/00

    摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

    摘要翻译： 含有类视黄醇衍生物和/或维生素A类似物作为成分的星形胶质细胞特异性药物载体; 一种使用该药物的药物递送方法; 含有该药物的药物; 以及使用该药物的治疗方法。 通过将药物载体与维生素A或维生素A类似物的类视黄醇衍生物结合或将其包封在药物载体中，用于治疗用途的药物可以特异性递送至星形胶质细胞。 结果，可以有效地有效地抑制或预防星形胶质细胞相关疾病，同时尽量减少副作用。 作为抑制星形胶质细胞活性或生长的药物，例如可以将作为胶原特异性分子伴侣的HSP47的siRNA包封在药物载体中。 因此，可以同时抑制I型至IV型胶原的分泌，从而可以有效地抑制纤维化。